Study of Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant
Do the drugs olaparib and abiraterone safe and effective to treat men who have metastatic
castration-resistant prostate cancer?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This study will determine if the drugs olaprib and abiraterone are safe, well-tolerated
and effective in treating metastatic castration-resistant prostate cancer. Metastatic
castration-resistant prostate cancer is when the cancer has spread to parts of the
body other than the prostate, and it is able to grow and spread even though drugs
or other treatments to lower the amount of male sex hormones are being used to manage
the cancer. Patients cannot have received prior chemotherapy or new hormonal agents
metastatic castration-resistant prostate cancer.
Approximately 720 patients globally will be randomized to treatment with either olaparib
and abiraterone or placebo and abiraterone.
Study Reference #: ULEU18130
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Haley Misch
Phone: (585) 275-9485
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search